Slide 1: Emma Walmsley, Chief Executive Officer
Emma Walmsley Chief Executive Officer 8 June 2021
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly t
Slide 3: Creating significant long-term shareholder value with two new companies
Creating significant long-term shareholder value with two new companies 2017 2022 Invest in R&D pipeline and Innovation improve productivity New GSK Sharpen commercial execution, refocus portfolio, drive cost Update June 23 2021 Performance discipline Address group structure and capital allocation N
Slide 4: Focused ESG approach to support delivery of long-term sustainable performance
Focused ESG approach to support delivery of long-term sustainable performance Pricing/Access Environment Global Health & Health Product governance security Inclusion & Diversity Operating standards 4
Slide 5: ESG areas of focus: Pricing and access
ESG areas of focus: Pricing and access Pricing/Access Environment Global Health & Health Product governance security Inclusion & Diversity Operating standards 5
Slide 6: ESG areas of focus: Global health and Health security
ESG areas of focus: Global health and Health security Environment Pricing/Access Environment Inclusion & Diversity Global Health & Health Pricing/Access Product governance security Inclusion & Diversity Operating standards 6
Slide 7: ESG areas of focus: Inclusion and Diversity
ESG areas of focus: Inclusion and Diversity Commitments to accelerate progress on I&D Pricing/Access Environment by 2025 Gender Increase female leaders (VP and above) to 45% globally Global Health & Health Product governance security Ethnicity Increase ethnically-diverse leaders (VP and above) to at
Slide 8: ESG areas of focus: Environment
ESG areas of focus: Environment Ambitious environmental targets Pricing/Access Environment Climate Net zero impact on climate action by 2030 Global Health/ health Nature Positive impact on nature Product governance security action by 2030 Inclusion & Diversity Operating standards 8
Slide 9: ESG areas of focus: Product Governance and Operating standards
ESG areas of focus: Product Governance and Operating standards Pricing/Access Environment Global Health/ health Product governance security Inclusion & Diversity Operating standards 9
Slide 10: Integrating ESG into operations to ensure delivery
Integrating ESG into operations to ensure delivery Integrated across operations and incentivised Benchmarked with visible public commitments Part of capital allocation approach 10
Slide 11: ESG leader in key ratings and indices
ESG leader in key ratings and indices Access to Dow Jones MSCI Sustainalytics Medicine Index Sustainability Index 1 st 2 nd AA 21.3 in the Pharma sector ESG risk rating CDP Science Vigeo Eiris Antimicrobial Based Targets Resistance A in water, B in Carbon, Accredited for 1.5OC 1 st benchmark Lead ph
Slide 12: ESG performance to deliver health impact and shareholder returns
ESG performance to deliver health impact and shareholder returns Sustainable performance and long-term growth New GSK to positively Trust for all stakeholders impact the health of Reduced risk to operations >2.5 bn people over 10 years Positive social impact 12
Slide 13: Q&A
Q&A